Archive · 20 Jan 2026
AI and GLP therapies key in tackling obesity crisis
Sangeeta Reddy from Apollo Hospitals talked about how important AI and new medicines like GLP therapies are in fighting obesity.
She said obesity is a big problem that can cause many other health issues.
GLP drugs like Ozempic can help, but they should be used carefully with a doctor's guidance.
AI is also making healthcare better by helping doctors work faster and more accurately.
For example, AI can detect diseases like liver problems early.
Reddy emphasized that while technology is helpful, doctors and nurses are still very important in healthcare.
Sangeeta Reddy highlighted the importance of AI and GLP therapies in tackling the obesity crisis.
GLP-based drugs like Ozempic, Wegovy, and Mounjaro are powerful but should be used judiciously under medical supervision.
AI is transforming healthcare by optimizing workflows, reducing waiting times, and assisting in clinical decision-making.
AI-driven tools can detect conditions like brain bleeds and non-alcoholic fatty liver disease (NAFLD) early.
Reddy emphasized that technology should augment, not replace, human judgment in healthcare.
- Who
- Sangeeta Reddy, Joint Managing Director of Apollo Hospitals Enterprise
- What
- Discussion on AI and GLP therapies for obesity and healthcare
- When
- Davos 2026
- Where
- Davos
- Why
- To address the growing obesity crisis and healthcare challenges
- Speaker
- Sangeeta Reddy, Joint Managing Director of Apollo Hospitals Enterprise
- Event
- Davos 2026
- GLP Therapies
- Ozempic, Wegovy, Mounjaro
- AI Applications
- Optimizing workflows, real-time clinical assistance, disease detection
- NAFLD Risk
- 40% of adults
- Healthcare Focus
- Preventive care, early disease detection